Cartesian Therapeutics (RNAC) Stock Analysis & Winston Score

Cartesian Therapeutics is a clinical-stage biotech company working on new medicines for autoimmune diseases — conditions where the body's immune system mistakenly attacks itself. The company focuses on RNA cell therapies, which are treatments that use engineered immune cells to target and reduce harmful immune responses. Its lead programs are aimed at diseases like myasthenia gravis and other serious autoimmune conditions, with patients and hospitals as the eventual end users. Cartesian makes no product revenue yet, as it is still running clinical trials and has not received regulatory approval for any therapy. It is based in the United States and is a small company, funded primarily through equity raises and partnerships rather than sales. The deeply negative margins reflect the high cost of early-stage drug development. The key growth driver is clinical trial success — particularly for its lead candidate, Descartes-08 — but the main risk is that trials could fail, which would put significant pressure on the company's ability to raise more funding and survive.